Rise and shine, everyone, the middle of the week has arrived. And this calls for a celebratory cup or two of stimulation. How so? Well, you made it this far, which can be an accomplishment, after all. Moreover, there is always good reason to forge ahead, given that there is so much more to do and the effort just might pay off. With this in mind, we have assembled the usual menu of tidbits for your perusal. Hope you have a smashing day and do drop us a line when you run across something interesting …

Dr. Craig Thompson, the chief executive of Memorial Sloan Kettering Cancer Center, plans to resign his seats on the boards of Merck (MRK) and Charles River Laboratories (CRL), The New York Times reports. The decision is the latest fallout from a widening institutional reckoning over relationships between cancer center leaders and for-profit health care companies. Thompson, 65, received $300,000 in compensation from Merck in 2017, and was paid $70,000 in cash by Charles River last year, plus $215,050 in stock.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • In the matter of the final item, why do I seem to hear the Regeneron worthies say “Rats!” in reaction to this turn of events?

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy